Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Monopar鈥檚 transition from early radiopharmaceutical trials to potential FDA milestones means wading through intricate disclosures. Users regularly ask, 鈥淲here can I read the Monopar Therapeutics quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I monitor Monopar Therapeutics insider trading Form 4 transactions before the market reacts?鈥� If you need Monopar Therapeutics SEC filings explained simply, Stock Titan removes the jargon and highlights what matters in minutes.
Our platform delivers Monopar Therapeutics 8-K material events explained the moment they hit EDGAR, alongside Monopar Therapeutics Form 4 insider transactions real-time alerts that pinpoint every share purchase, option grant, or sale. Interactive dashboards turn each Monopar Therapeutics annual report 10-K simplified into clear talking points and supply concise Monopar Therapeutics earnings report filing analysis that ties R&D spend, cash runway, and trial timelines together鈥攊deal for quick decision making.
Capital raises and clinical risk make management signals essential, so understanding Monopar Therapeutics SEC documents with AI goes further: compare Monopar Therapeutics proxy statement executive compensation to peer norms or spot sentiment shifts via Monopar Therapeutics executive stock transactions Form 4. Whether you鈥檙e checking toxicology data for MNPR-101 or gauging partnership amendments, Stock Titan鈥檚 AI surfaces every footnote, ratio, and red-flag update without digging through PDFs. Stay current, stay informed, and act confidently.
Monopar Therapeutics Inc. (MNPR) filed an 8-K reporting that on August 12, 2025 the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1. The filing also lists an Inline XBRL cover page as Exhibit 104, and provides the company headquarters in Wilmette, Illinois and Nasdaq listing information.
The 8-K explicitly states the Item 2.02 disclosure and the exhibit are being furnished, not filed, and therefore are not subject to Section 18 liability or incorporation by reference except as expressly stated in another filing. The report is signed by Quan Vu, Chief Financial Officer, dated August 12, 2025. The filing text does not include the press release content or numeric financial results.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs. At June 30, 2025, the company held $39,501,936 in cash and $13,748,473 in investments (about $53.3 million combined), and management estimates these funds are sufficient to fund operations at least through December 31, 2026. The balance sheet shows low total liabilities of $1.66 million and stockholders' equity of $52.2 million, with an accumulated deficit of approximately $80.9 million.
For the six months ended June 30, 2025, Monopar reported a net loss of $5,078,498 (basic and diluted net loss per share $0.73$3.37 million and general and administrative expense of $3.08 million year-to-date. Corporate developments include a transfer of IND sponsorship for ALXN1840 to Monopar effective June 6, 2025 with FDA acknowledgement on July 29, 2025. The company remains dependent on additional financing, faces milestone and royalty obligations under the Alexion license, and discloses execution risks related to regulatory review, radioisotope supply, and commercial adoption.
Monopar Therapeutics Inc. (MNPR) 鈥� Form 144 filing
An insider intends to sell up to 8,904 common shares through Merrill Lynch on or about 14 July 2025. The proposed sale, valued at $356,160, stems from two stock-option exercises (4,200 options granted 04 Apr 2016 and 4,704 options granted 20 Feb 2017), both to be settled in cash. The filing lists 6,115,214 shares outstanding, making the planned disposition roughly 0.15 % of the float. No other sales were reported in the past three months. The signer affirms no undisclosed material adverse information.
Form 144 is a notice, not an executed trade, but it flags potential insider activity. Given the small fraction of outstanding shares, immediate market impact should be limited; nevertheless, investors often track such filings for sentiment shifts.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
